

Kirkpatrick & Lockhart LLP

1800 Massachusetts Avenue, NW
Second Floor
Washington, DC 20036-1221
202.778.9000
www.kl.com

August 22, 2001

Center For Drug Evaluation
RECEIVED
AUG 22 2001
Office of
Regulatory Policy
And Research

0757 01 AUG 24 21 52
Kathleen D. Jaeger
202.778.9045
Fax: 202.778.9100
kjaeger@kl.com

Mary Catchings
Office of Regulatory Policy
1451 Rockville Pike
HFD - 7; WOC II
Rockville, Maryland 20852


Re: Withdrawal of Citizen Petition: Alternate Reference Listed Drug
Docket : 99P-2146 CP1: June 30, 1999

Dear Mary:

This letter is to confirm our telephone conversation of August 14, 2001 regarding the above-petitioned Citizen Petition. We submitted this petition on behalf of a client on June 30, 1999 which requested FDA to designate Fosamax® 10mg oral tablets, manufactured by Merck, as an alternate reference listed drug. Because this is no longer a relevant issue for our client, we hereby withdraw our Citizen Petition (99P-2146CP1) without prejudice.

Should you have any questions regarding this issue, please feel free to contact me.

Sincerely,


Kathleen D. Jaeger

99P-2146

WDL1

DC-461052 v1 0306556-0100



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

Memorandum

Date . August 23, 2001
From Mary Catchings (HFD-7) *M. Catchings*
Subject Docket No. 99P-2146/CP1
To Dockets Management Branch (HFA-305)

0758 01 26 24 21 52

Please file the attached letter from Kathleen Jaeger (Kirkpatrick & Lockhart, LLP) dated August 22, 2001, in the docket indicated above. The letter withdraws the citizen petition filed in the docket.

Thank you.

Attachment